These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23565041)

  • 1. The risky reliance on small surrogate endpoint studies when planning a large prevention trial.
    Baker SG; Kramer BS
    J R Stat Soc Ser A Stat Soc; 2013 Feb; 176(2):603-608. PubMed ID: 23565041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surrogate endpoint analysis: an exercise in extrapolation.
    Baker SG; Kramer BS
    J Natl Cancer Inst; 2013 Mar; 105(5):316-20. PubMed ID: 23264679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five criteria for using a surrogate endpoint to predict treatment effect based on data from multiple previous trials.
    Baker SG
    Stat Med; 2018 Feb; 37(4):507-518. PubMed ID: 29164641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surrogate Endpoint Evaluation: Principal Stratification Criteria and the Prentice Definition.
    Gilbert PB; Gabriel EE; Huang Y; Chan IS
    J Causal Inference; 2015 Sep; 3(2):157-175. PubMed ID: 26722639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surrogate endpoints in clinical trials: definition and operational criteria.
    Prentice RL
    Stat Med; 1989 Apr; 8(4):431-40. PubMed ID: 2727467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the Prentice criterion validate surrogate endpoints?
    Berger VW
    Stat Med; 2004 May; 23(10):1571-8. PubMed ID: 15122737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surrogate endpoint evaluation using data from one large global randomized controlled trial.
    Geybels M; Wolthers BO; Kreiner FF; Rasmussen S; Bauer R
    BMC Med Inform Decis Mak; 2021 May; 21(1):164. PubMed ID: 34016120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two simple approaches for validating a binary surrogate endpoint using data from multiple trials.
    Baker SG
    Stat Methods Med Res; 2008 Oct; 17(5):505-14. PubMed ID: 18285436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A perfect correlate does not a surrogate make.
    Baker SG; Kramer BS
    BMC Med Res Methodol; 2003 Sep; 3():16. PubMed ID: 12962545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adapting the sample size planning of a phase III trial based on phase II data.
    Wang SJ; Hung HM; O'Neill RT
    Pharm Stat; 2006; 5(2):85-97. PubMed ID: 17080765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES).
    Lassere MN; Johnson KR; Schiff M; Rees D
    BMC Med Res Methodol; 2012 Mar; 12():27. PubMed ID: 22409774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rank test for bivariate time-to-event outcomes when one event is a surrogate.
    Shaw PA; Fay MP
    Stat Med; 2016 Aug; 35(19):3413-23. PubMed ID: 27059817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surrogate endpoints in clinical trials: cardiovascular diseases.
    Wittes J; Lakatos E; Probstfield J
    Stat Med; 1989 Apr; 8(4):415-25. PubMed ID: 2727465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
    Sertdemir Y; Burgut R
    Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised controlled trial is not a pilot trial simply because it uses a surrogate endpoint.
    Campbell MJ; Lancaster GA; Eldridge SM
    Pilot Feasibility Stud; 2018; 4():130. PubMed ID: 30069309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating Covariates into Measures of Surrogate Paradox Risk.
    Shafie Khorassani F; Taylor JMG; Kaciroti N; Elliott MR
    Stats (Basel); 2023 Mar; 6(1):322-344. PubMed ID: 37885610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical evaluation of surrogate endpoints with examples from cancer clinical trials.
    Buyse M; Molenberghs G; Paoletti X; Oba K; Alonso A; Van der Elst W; Burzykowski T
    Biom J; 2016 Jan; 58(1):104-32. PubMed ID: 25682941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint.
    Baker SG
    Biostatistics; 2006 Jan; 7(1):58-70. PubMed ID: 15972889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical Validation of Surrogate Endpoints: Another Look at the Prentice Criterion and Other Criteria.
    Saraf S; Mathew T; Roy A
    J Biopharm Stat; 2015; 25(6):1234-46. PubMed ID: 25372337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.